New Anticoagulant Targets Beyond Factor Xa Explored
Why Look Beyond Factor Xa
Despite gains since direct oral anticoagulants reached market around 2011, current drugs still carry limitations: gastrointestinal bleeding, cytochrome drug interactions, restricted use in kidney or liver disease, and no option for antiphospholipid syndrome or mechanical heart valves. The speaker framed the core challenge as decoupling pathologic clotting from the body’s normal, protective clotting response.
Factor XI As A Distinct Target
Factor XI sits upstream in the clotting cascade and appears more important for pathologic thrombosis than hemostasis, since people born with factor XI deficiency rarely bleed abnormally and need only small blood-product doses before major surgery. Two agents were highlighted: abelacimab, a once-monthly antibody against factor XI and XIa, and milvexian, an oral inhibitor, both aiming to cut clotting risk with less bleeding.
Early Clinical Evidence
In an AFib trial, abelacimab showed less major bleeding than rivaroxaban, and pooled knee-replacement data suggested factor XI inhibition can outperform low molecular weight heparin after surgery, with milvexian now tested in cancer patients. The speaker cautioned not every agent succeeds, noting one factor XII inhibitor trial stopped early for reduced effectiveness.
